AstraZeneca Phase II Exanta stroke data

AstraZeneca (AZN; LSE:AZN) said that in an open-label continuation of its 125-patient Phase II SPORTIF II study, preliminary data showed that Exanta patients had 0.9 strokes and 0.4 transient ischemic...